U.S., April 10 -- ClinicalTrials.gov registry received information related to the study (NCT06918015) titled 'Zanubrutinib Plus GCVP (Obinutuzumab, Cyclophosphamide, Vindesine, Prednisolone) in Previously Untreated Follicular Lymphoma' on March 20.
Brief Summary: Previously untreated patients with follicular lymphoma are treated with the ZGCVP regimen (zanubrutinib, obinutuzumab, cyclophosphamide, vindesine, prednisolone) for 6 cycles.
Study Start Date: May 01
Study Type: INTERVENTIONAL
Condition:
BTK Inhibitors
Follicular Lymphoma
Immunochemotherapy
Intervention:
DRUG: ZGCVP
Patients receive the ZGCVP regimen (zanubrutinib, obinutuzumab, cyclophosphamide, vindesine, prednisolone) for 6 cycles at the following dose:
1. Zanubrutinib...